Evidence map›Paper›PMID 37638005›Full record

ArticleFrontiers in immunology2023

Prognostic and tumor microenvironmental feature of clear cell renal cell carcinoma revealed by m6A and lactylation modification-related genes.

Lin Yang, Xiaoyu Wang, Jiahao Liu, Xiaoqiang Liu, Sheng Li, Fuchun Zheng, Qianxi Dong, Songhui Xu, Jing Xiong, Bin Fu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lin YangDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaoyu WangDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiahao LiuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaoqiang LiuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Sheng LiDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Fuchun ZhengDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Qianxi DongDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Songhui XuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Jing XiongDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Bin FuDepartment of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
First Affiliated Hospital of Nanchang University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Both lactylation and m6A modification have important implications for the development of clear cell renal cell carcinoma (ccRCC), and we aimed to use crosstalk genes of both to reveal the prognostic and immunological features of ccRCC. Methods: Our first step was to look for lactylation-related genes that differed between normal and tumor tissues, and then by correlation analysis, we found the genes associated with M6A. Following that, ccRCC subtypes will be identified and risk models will be constructed to compare the prognosis and tumor microenvironment among different subgroups. A nomogram was constructed to predict the prognosis of ccRCC, and Results: We screened 100 crosstalk genes and identified 2 ccRCC subtypes. A total of 11 prognostic genes were screened for building a risk model. we observed higher immune scores, elevated tumor mutational burden, and microsatellite instability scores in the high-risk group. Therefore, individuals classified as high-risk would derive greater benefits from immunotherapy. The nomogram's ability to predict overall survival with a 1-year AUC of 0.863 demonstrates its significant practical utility. In addition, HIBCH was identified as a potential therapeutic target and its expression and function were verified by Conclusion: In addition to developing a precise prognostic nomogram for patients with ccRCC, our study also discovered the potential of HIBCH as a biomarker for the disease.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsHumansPrognosisTumor Microenvironmentclear cell renal cell carcinomaimmunotherapylactylationM6Atumor microenvironment

Identifiers

PMID37638005
PMCPMC10450969
OpenAlexW4385758600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.